Affymax and Takeda are collaborating on the development of Hematide(TM). The product will be commercialized in the European Union by Takeda. Affymax is conducting Phase 3 clinical trials for Hematide(TM) to treat anemia in chronic renal failure indications. Takeda is also focusing on a recently initiated Phase 1 clinical trial to evaluate Hematide(TM) to treat chemotherapy-induced anemia in prostate, breast and non-small cell lung cancer patients. Hematide(TM) is a trademark of Affymax.
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
This press release contains forward-looking statements regarding the
potential of Hematide(TM), the potential of Nektar's PEGylation Technology,
and the overall prospects for Nektar's business. These forward-looking
statements involve important risks and uncertainties, including but not
limited to: (i) because Hematide(TM) is still in clinical development, the
risk of failure is high and can occur at any stage due to many factors
including but not limited to safety and efficacy considerations; (ii)
Takeda and Affymax may fail to obtain regulatory approval for Hematide(TM)
in one or more indications; (iii) if Hematide(TM) does receive regulatory
approval, Nektar's actua
|SOURCE Nektar Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved